Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

The US delivers Lenacapavir HIV treatment to Eswatini and Zambia, expanding prevention efforts despite prior aid cuts under ...

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...

Sofosbuvir, a hepatitis C treatment drug, can adversely interact with tenofovir disoproxil, a HIV treatment drug, according to research led by Bingfang Yan, PhD, professor of biomedical and ...

The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...